Clinical Trial Update: Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating durvalumab and tremelimumab with radiotherapy in recurrent or metastatic gynecologic cancers has been terminated; no efficacy results a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Endometrial Cancer
• Ovarian Cancer
• Vaginal Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Recurrent Gynecological Cancer, Metastatic Cervical Cancer | Phase 1 | Status: TERMINATED